MCA Stability Tool

This recommendation is based on the products Zyloric 100mg tablets (Aspen) and Allopurinol 100mg tablets (Ipca Laboratories Ltd) and Allopurinol 200mg tablets (Aspire Pharma).

Use with caution

Allopurinol 100mg tablets (Accord-UK Ltd)

Explore other Allopurinol formulations Explore other Allopurinol 100mg tablets suppliers

Stability Notes

Manufacturer recommends storing in original container. Protect from light. Anecdotal reports of use in MCAs (low quality evidence).

Provenance

This recommendation is based on the products Zyloric 100mg tablets (Aspen) and Allopurinol 100mg tablets (Ipca Laboratories Ltd) and Allopurinol 200mg tablets (Aspire Pharma).

Use with caution

Allopurinol 100mg tablets (Alliance Healthcare (Distribution) Ltd)

Explore other Allopurinol formulations Explore other Allopurinol 100mg tablets suppliers

Stability Notes

Manufacturer recommends storing in original container. Protect from light. Anecdotal reports of use in MCAs (low quality evidence).

Provenance

This recommendation is based on the products Zyloric 100mg tablets (Aspen) and Allopurinol 100mg tablets (Ipca Laboratories Ltd) and Allopurinol 200mg tablets (Aspire Pharma).

Use with caution

Allopurinol 100mg tablets (Almus Pharmaceuticals Ltd)

Explore other Allopurinol formulations Explore other Allopurinol 100mg tablets suppliers

Stability Notes

Manufacturer recommends storing in original container. Protect from light. Anecdotal reports of use in MCAs (low quality evidence).

Provenance

This recommendation is based on the products Zyloric 100mg tablets (Aspen) and Allopurinol 100mg tablets (Ipca Laboratories Ltd) and Allopurinol 200mg tablets (Aspire Pharma).

Use with caution

Allopurinol 100mg tablets (Amarox Ltd)

Explore other Allopurinol formulations Explore other Allopurinol 100mg tablets suppliers

Stability Notes

Manufacturer recommends storing in original container. Protect from light. Anecdotal reports of use in MCAs (low quality evidence).

Provenance

This recommendation is based on the products Zyloric 100mg tablets (Aspen) and Allopurinol 100mg tablets (Ipca Laboratories Ltd) and Allopurinol 200mg tablets (Aspire Pharma).

Use with caution

Allopurinol 100mg tablets (Bristol Laboratories Ltd)

Explore other Allopurinol formulations Explore other Allopurinol 100mg tablets suppliers

Stability Notes

Manufacturer recommends storing in original container. Protect from light. Anecdotal reports of use in MCAs (low quality evidence).

Provenance

This recommendation is based on the products Zyloric 100mg tablets (Aspen) and Allopurinol 100mg tablets (Ipca Laboratories Ltd) and Allopurinol 200mg tablets (Aspire Pharma).

Use with caution

Allopurinol 100mg tablets (Crescent Pharma Ltd)

Explore other Allopurinol formulations Explore other Allopurinol 100mg tablets suppliers

Stability Notes

Manufacturer recommends storing in original container. Protect from light. Anecdotal reports of use in MCAs (low quality evidence).

Provenance

This recommendation is based on the products Zyloric 100mg tablets (Aspen) and Allopurinol 100mg tablets (Ipca Laboratories Ltd) and Allopurinol 200mg tablets (Aspire Pharma).

Use with caution

Allopurinol 100mg tablets (Ennogen Healthcare International Ltd)

Explore other Allopurinol formulations Explore other Allopurinol 100mg tablets suppliers

Stability Notes

Manufacturer recommends storing in original container. Protect from light. Anecdotal reports of use in MCAs (low quality evidence).

Provenance

This recommendation is based on the products Zyloric 100mg tablets (Aspen) and Allopurinol 100mg tablets (Ipca Laboratories Ltd) and Allopurinol 200mg tablets (Aspire Pharma).

Use with caution

Allopurinol 100mg tablets (Flamingo Pharma (UK) Ltd)

Explore other Allopurinol formulations Explore other Allopurinol 100mg tablets suppliers

Stability Notes

Manufacturer recommends storing in original container. Protect from light. Anecdotal reports of use in MCAs (low quality evidence).

Provenance

This recommendation is based on the products Zyloric 100mg tablets (Aspen) and Allopurinol 100mg tablets (Ipca Laboratories Ltd) and Allopurinol 200mg tablets (Aspire Pharma).

Use with caution

Allopurinol 100mg tablets (Genesis Pharmaceuticals Ltd)

Explore other Allopurinol formulations Explore other Allopurinol 100mg tablets suppliers

Stability Notes

Manufacturer recommends storing in original container. Protect from light. Anecdotal reports of use in MCAs (low quality evidence).

Provenance

This recommendation is based on the products Zyloric 100mg tablets (Aspen) and Allopurinol 100mg tablets (Ipca Laboratories Ltd) and Allopurinol 200mg tablets (Aspire Pharma).

Use with caution

Allopurinol 100mg tablets (Ipca Laboratories UK Ltd)

Explore other Allopurinol formulations Explore other Allopurinol 100mg tablets suppliers

Stability Notes

Manufacturer recommends storing in original container. Protect from light. Anecdotal reports of use in MCAs (low quality evidence).

Provenance

This recommendation is based on the products Zyloric 100mg tablets (Aspen) and Allopurinol 100mg tablets (Ipca Laboratories Ltd) and Allopurinol 200mg tablets (Aspire Pharma).

Use with caution

Allopurinol 100mg tablets (Manx Healthcare Ltd)

Explore other Allopurinol formulations Explore other Allopurinol 100mg tablets suppliers

Stability Notes

Manufacturer recommends storing in original container. Protect from light. Anecdotal reports of use in MCAs (low quality evidence).

Provenance

This recommendation is based on the products Zyloric 100mg tablets (Aspen) and Allopurinol 100mg tablets (Ipca Laboratories Ltd) and Allopurinol 200mg tablets (Aspire Pharma).

Print this list

Compatible

Medicines suitable for use in MCAs, although use is likely to be off-label.  Keep medicines in MCAs for the shortest time necessary. Generally, up to 5 weeks maximum unless otherwise specified, or consider up to 8 weeks if the MCA is airtight (sealed).  Consider the risk to the individual from potency loss or dose variability, particularly with unsealed devices.  Monitor for any changes in therapeutic effect or increased adverse effects after MCA initiation.

Use with caution

There are concerns about stability and/or there is a lack of stability data available. These medicines can theoretically be used in MCAs, although use is likely to be off-label.  Mitigation measures may need to be considered.  Keep medicines in MCAs for the shortest time necessary.  Generally, up to 5 weeks maximum unless otherwise specified, or consider up to 8 weeks if the MCA is airtight (sealed). Consider the risk to the individual from potency loss or dose variability, particularly with unsealed devices. Monitor for any changes in therapeutic effect or increased adverse effects after MCA initiation.

Incompatible

Medicines under this category are not suitable for use in MCAs.

No Stability Information

These medicines have not been reviewed by SPS.